To:

From the INTERNATIONAL BUREAU

PCT


NOTIFICATION OF TRANSMITTAL
OF COPIES OF TRANSLATION
OF THE INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY
(CHAPTER I OR CHAPTER II
OF THE PATENT COOPERATION TREATY)

(PCT Rules 44bis.3(c) and 72.2)

Ohshima Patent Office
BN Gyoen Building
17-11, Shinjuku 1-chome
Shinjuku-ku, Tokyo 160-0022

OHSHIMA, Masataka

JAPÓN



Date of mailing (day/month/year) 06 July 2006 (06.07.2006)	
Applicant's or agent's file reference G50PH	IMPORTANT NOTIFICATION
International application No. PCT/JP2004/014774	International filing date (day/month/year) 30 September 2004 (30.09.2004)
Applicant O	PHTECS CORPORATION et al

1	Transmittal	of the	translation	to	the applicant.
1.		OT MIC		w	mic applicans

v	The International Bureau transmits herewith a copy of the English translation of the international preliminary report or patentability (Chapter I).
L	patentability (Chapter I).

The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter II).

2. Transmittal of the copy of the translation to the designated or elected Offices.

The International Bureau notifies the applicant that copies of that translation have been transmitted to the following designated or elected Offices requiring such translation:

None

The following designated or elected Offices, having waived the requirement for such a transmittal at this time, will receive copies of that translation from the International Bureau only upon their request:

AE, AG, AL, AM, AP, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EA, EC, EE, EG, EP, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OA, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

3. Reminder regarding translation into (one of) the official language(s) of the elected Office(s).

The applicant is reminded that, where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability (Chapter Π).

It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned within the applicable time limit (Rule 74.1). See Volume II of the PCT Applicant's Guide for further details.

Authorized officer

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference G50PH	FOR FURTHER ACTION	See item 4 below	
International application No. PCT/JP2004/014774	International filing date (day/month/year) 30 September 2004 (30.09.2004)	Priority date (day/month/year) 06 October 2003 (06.10.2003)	
International Patent Classification (8th See relevant information in Form P	edition unless older edition indicated) CT/ISA/237		
Applicant OPHTECS CORPORATION			

1.	This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis.1(a).				
2.	This REPORT consists of a total of 6 sheets, including this cover sheet.				
	In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.				
3.	This report contains indications relating to the following items:				
	Box No. I	Basis of the report			
	Box No. II	Priority			
	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			
	Box No. IV	Lack of unity of invention			
	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
	Box No. VI	Certain documents cited			
	Box No. VII	Certain defects in the international application			
	Box No. VIII	Certain observations on the international application			
4.	The International Bureau will not, except where the applicandate (Rule 44bis .2).	communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but at makes an express request under Article 23(2), before the expiration of 30 months from the priority			

	Date of issuance of this report 26 June 2006 (26.06.2006)
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Masashi Honda
Facsimile No. +41 22 338 82 70	e-mail: pt08@wipo.int

PATENT COOPERATION TREATY

TRANSLATION From the INTERNATIONAL SEARCHING AUTHORITY To: PCT WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) Applicant's or agent's file reference FOR FURTHER ACTION G5OPH See paragraph 2 below Priority date (day/month/year) International application No. International filing date (day/month/year) 06.10.2003 PCT/JP2004/014774 30.09.2004 International Patent Classification (IPC) or both national classification and IPC Applicant OPHTECS CORPORATION This opinion contains indications relating to the following items: Box No. I Basis of the opinion Box No. II Priority Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. III Box No. IV Lack of unity of invention Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application **FURTHER ACTION** 2. If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. 3. Name and mailing address of the ISA/JP Authorized officer

Telephone No.

Facsimile No.

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/JP2004/014774

Box	No. I Basis of this opinion	
1.	With regard to the language, this opinion has been established on the basis of the international application in the language in which it filed, unless otherwise indicated under this item.	was
	This opinion has been established on the basis of a translation from the original language into the following language	
	, which is the language of a translation furnished for the purposes of international search (un	der
	Rule 12.3 and 23.1(b)).	
2.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claim invention, this opinion has been established on the basis of:	med
	a. type of material	
: :	a sequence listing	
	table(s) related to the sequence listing	
	b. format of material	
	in written format	
	in computer readable form	
	c. time of filing/furnishing	
	contained in the international application as filed.	
	filed together with the international application in computer readable form.	
	furnished subsequently to this Authority for the purposes of search.	
3.	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been file furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application filed or does not go beyond the application as filed, as appropriate, were furnished.	
4.	Additional comments:	

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

Ð

International application No.
PCT/JP2004/014774

Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
	ons whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially have not been examined in respect of:
	the entire international application
\boxtimes	claims Nos. 12-14
because	
	the said international application, or the said claims Nos. 12-14
	relate to the following subject matter which does not require an international preliminary examination (specify):
	The subject matters of claims 12-14 relate to a method for treatment of the human or animal
	body by therapy, which does not require an international preliminary examination by the
	International Preliminary Examining Authority in accordance with PCT Article 34(4)(a)(i) and
	Rule 67.1(iv).
	the description, claims or drawings (indicate particular elements below) or said claims Nos.
	are so unclear that no meaningful opinion could be formed (specify):
	the claims, or said claims Nos. are so inadequately supported
	by the description that no meaningful opinion could be formed.
\bowtie	no international search report has been established for said claims Nos. 12-14
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:
	the written form has not been furnished
	does not comply with the standard
	the computer readable form has not been furnished
	does not comply with the standard
	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.
	See Supplemental Box for further details.

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/JP2004/014774

	citations and expla	nations su	pporting such statement	· · · · · · · · · · · · · · · · · · ·
1.	Statement			
	Novelty (N)	Claims	1-11	YES
		Claims		NO
	Inventive step (IS)	Claims Claims	1-11	YES NO
	Industrial applicability (IA)	Claims Claims	1-11	YES NO

Reasoned statement under Rule 43bis, 1(a)(i) with regard to novelty, inventive step or industrial applicability:

2. Citations and explanations:

Box No. V

Document 1: JP, 10-265378, A (Ophtecs Corp.), 6 October, 1998 (06.10.98)

Document 2: Hitoshi WATANABE, The Journal of the Eye, 1997, Vol.14, No.11, pages 1647-1653

Document 3: Ikuko TODA, et al., The Journal of the Eye, 1991, Vol.8, No.7, pages 1021-1027

Document 4: Satoshi SUZUKI, et al., Nichigankaishi, 1997, Vol.101, No.1, pages 52-56

Document 5: Tsutomu INATOMI, Journal of Japan Contact Lens Society, 1999, Vol.41, No.4, pages S7-S13

Document 6: Murato Doru, The Japanese journal of ophthalmic caring, 1 May, 2003 (01.05.03), Vol.5, No.5, pages 406-410

Document 7: ZHANG, Y. L. et al, Journal of Colloid and Interface Science, 1 June, 2003 (01.06.03), Vol.262, No.1, pages 130-148

* Claims 1-11:

The subject matters of claims 1-11 do not appear to involve an inventive step in view of documents 1-7 cited in the ISR.

Document 1 describes that 3-hydroxybutyric acid and/or its salt have a good therapeutic effect on corneal epithelial damage. Since document1 does not describe an effect for lacrimal disorders, however, the subject matters of claims 1-11 of the present application differ from that described in document1.

As described in the documents 2-7, however, a person skilled in the art knows well that corneal epithelium closely involves stabilization and retention of lacrimal layer, a person skilled in the art could have easily conceived the idea of using 3-hydroxybutyric acid and/or its salt for treating lacrimal disorders.